Nirmatrelvir combined with ritonavir for preventing and treating COVID-19-Reference-Cited by-同舟云学术

Nirmatrelvir combined with ritonavir for preventing and treating COVID-19

Published:2022-09-20 Issue:9 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Reis Stefanie¹,Metzendorf Maria-Inti²,Kuehn Rebecca³,Popp Maria¹,Gagyor Ildiko⁴,Kranke Peter¹,Meybohm Patrick¹,Skoetz Nicole⁵,Weibel Stephanie¹

Affiliation:

1. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital Würzburg; Würzburg Germany

2. Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine University Düsseldorf; Düsseldorf Germany

3. Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK

4. Department of General Practice; University Hospital Würzburg; Würzburg Germany

5. Cochrane Haematology, Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne; Center for Integrated Oncology, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference113 articles.

1. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;New England Journal of Medicine,2022

2. Norisuke K jRCT2031210267: A study of PF-07321332/ritonavir in nonhospitalized high risk adult participants with COVID-19 jrct.niph.go.jp/en-latest-detail/jRCT2031210267

3. 2021-002895-38: A phase 2/3 efficacy and safety study of PF-07321332 /ritonavir in nonhospitalized high risk adult participants with COVID 19 clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38

4. NCT04960202: EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 clinicaltrials.gov/ct2/show/NCT04960202

5. Cautious optimism and considerations for health providers and patients: oral antiviral for early treatment of high-risk patients and vaccines for prevention of COVID-19;Caceres;American Journal of Medicine,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function;Antimicrobial Agents and Chemotherapy;2024-08-07

2. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir;Infectious Diseases and Therapy;2024-06-03

3. An umbrella review on treatments and therapeutic options for COVID-19;Russian Journal of Infection and Immunity;2023-11-30

4. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19;Cochrane Database of Systematic Reviews;2023-11-30

5. Medical technologies assessment in COVID-19;HIV Infection and Immunosuppressive Disorders;2023-10-21